中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.019 seconds)

    MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF
    1.
    发明申请
    MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF 审中-公开
    改性释放的拉米夫定组合物及其用途

    公开(公告)号：WO2010029571A2

    公开(公告)日：2010-03-18

    申请号：PCT/IN2009/000428

    申请日：2009-07-28

    Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  SINGH, Sarabjit

    Inventor： JAIN, Rajesh ,  SINGH, Sarabjit

    IPC: A61K9/22 ,  A61K31/403

    CPC classification number: A61K9/4808 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2846 ,  A61K31/403

    Abstract: The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.

    Abstract translation: 本发明涉及包含雷米普利或其药学上可接受的盐和药学上可接受的赋形剂的调控释放药物组合物，其中药物组合物与每天两次施用的雷米普利的常规即释制剂生物等效。 本发明进一步涉及调控释放药物组合物，其包含：包含雷米普利或其药学上可接受的盐的速释组分和包含雷米普利或其药学上可接受的盐的调控释放组分。 本发明进一步涉及制备雷米普利改良释放药物组合物的方法。

    COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF BUPROPION
    5.
    发明申请
    COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF BUPROPION 审中-公开
    更好地提供BUPROPION的组合物和方法

    公开(公告)号：WO2009050726A2

    公开(公告)日：2009-04-23

    申请号：PCT/IN2008/000337

    申请日：2008-05-28

    Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PRASAD, Korlakunte ,  JAIN, Rajesh

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PRASAD, Korlakunte ,  JAIN, Rajesh

    IPC: A61K9/50 ,  A61K31/137

    CPC classification number: A61K31/137 ,  A61K9/0043 ,  A61K9/141 ,  A61K9/48 ,  A61K9/5021

    Abstract: The present invention provides a pharmaceutical composition comprising micronized bupropion having controlled particle size in the range between 1-60 μm. The pharmaceutical composition of the present invention comprises micronized bupropion having median particle size less than 40 micron, which exhibits outstanding bioavailability via nasal and pulmonary route even without any need for blending the micronized bupropion with large carrier particles. The composition of the present invention comprises micronized bupropion -and one or more pharmaceutically acceptable carriers, surfactants, a dispersing agents, or dispersants, which can be administered in an aerosol formulation as a dry powder for nasal and pulmonary inhalation. Particularly, the composition of the present invention for nasal delivery comprises bioadhesive microparticles of bupropion and carbohydrates like pullulan to prevent and treat diseases such as depression, premenstrual syndrome, premature ejaculation and as an aid to smoking cessation. The invention also provides a process of preparing the compositions of the present invention.

    Abstract translation: 本发明提供了一种药物组合物，其包含具有在1-60μm范围内的可控粒度的微粉化安非他酮。 本发明的药物组合物包含中值粒度小于40微米的微粉化安非他酮，其即使不需要将微粉化安非他酮与大载体颗粒共混，也通过鼻和肺部途径表现出优异的生物利用度。 本发明的组合物包含微粉化安非他酮以及一种或多种药学上可接受的载体，表面活性剂，分散剂或分散剂，其可以作为用于鼻和肺吸入的干粉以气雾剂形式给药。 特别地，用于鼻腔递送的本发明组合物包含安非他酮和碳水化合物如普鲁兰多糖的生物粘附微粒，以预防和治疗诸如抑郁症，经前期综合征，早泄和诸如戒烟的辅助之类的疾病。 本发明还提供了制备本发明组合物的方法。

    MODIFIED DOSAGE FORMS OF TACROLIMUS
    6.
    发明申请
    MODIFIED DOSAGE FORMS OF TACROLIMUS 审中-公开
    TACROLIMUS的改良剂型

    公开(公告)号：WO2009022354A2

    公开(公告)日：2009-02-19

    申请号：PCT/IN2008/000179

    申请日：2008-03-25

    Applicant: PANACEA BIOTEC LIMITED. ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  JAIN, Rajesh

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  JAIN, Rajesh

    IPC: A61K9/22 ,  A61K31/341 ,  A61K31/365

    CPC classification number: A61K9/146 ,  A61K9/1676 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/436

    Abstract: The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.

    Abstract translation: 本发明提供了在口服给药后释放两种或更多量他克莫司的他克莫司的改良释放剂型，基本上立即在0-2小时内立即释放剂量单位中的第一量他克莫司释放 随后是约1-10小时的时间间隔，在此期间基本上没有量的他克莫司从剂型释放，此后释放第二量的他克莫司，其中所述第二量从缓释剂量单位立即释放，例如立即释放 在0-2小时内或在从其最初从缓释剂量单位释放约2-12小时的时间范围内。 剂型可以进一步包含额外量的他克莫司以提供额外的他克莫司脉冲。 他克莫司的剂型表现出比现有组合物他克莫司改善的生物利用度和减少的通量或波动。 还描述了制备剂型的方法。

    PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF
    7.
    发明申请
    PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF 审中-公开
    用于输送活性成分的颗粒，其制备方法及其组合物

    公开(公告)号：WO2008062429A2

    公开(公告)日：2008-05-29

    申请号：PCT/IN2007/000340

    申请日：2007-08-10

    Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  SINGH, Paramjit ,  JAIN, Rajesh

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  SINGH, Paramjit ,  JAIN, Rajesh

    IPC: B82B3/00 ,  A61K9/00

    CPC classification number: A61K9/19 ,  A61K9/5115 ,  A61K9/5161 ,  A61K9/5192 ,  B82Y5/00

    Abstract: The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.

    Abstract translation: 本发明公开了具有无机元素的颗粒的组合物， 一种或多种活性成分和任选的释放速率调节剂，适于向人和动物组织递送活性成分。 颗粒是优选通过溶胶 - 凝胶法制备的纳米颗粒或微粒或其混合物。 该组合物可用于局部或粘膜表面，优选以乳膏，凝胶，洗剂，干粉，喷雾，泡沫和其它合适的形式施用。

    METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS 审中-公开
    用于生产抗坏血酸作用的方法和组合物

    公开(公告)号：WO2008068770A2

    公开(公告)日：2008-06-12

    申请号：PCT/IN2007/000274

    申请日：2007-07-05

    Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    IPC: A61K31/167 ,  A61K31/10 ,  A61K9/20

    CPC classification number: A61K31/10 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/167

    Abstract: The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.

    Abstract translation: 本发明提供了一种用于在哺乳动物中产生抗雄激素作用的方法和组合物。 该方法包括向哺乳动物施用改性释放的药物组合物，其具有降低的给药频率，以改善患者的便利性和依从性。 与常规比卡鲁胺组合物相比，本发明的组合物还提供更高的生物利用度和改善的药代动力学特征。

    PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY
    9.
    发明申请
    PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY 审中-公开
    可编程交付技术

    公开(公告)号：WO2008062440A2

    公开(公告)日：2008-05-29

    申请号：PCT/IN2007/000392

    申请日：2007-09-03

    Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  TANDALE, Rajendra

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  TANDALE, Rajendra

    IPC: A61K9/24

    CPC classification number: A61K9/0065 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/2886

    Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the system can be retained in the gastric region for a prolonged period of time. It comprises of a core, one or more layers coated over the core and a preformed hollow space. The invention also concerns with a process for preparation of the system and a method for treating/preventing diseases, by administering to a subject in need thereof, the system of the invention.

    Abstract translation: 本发明涉及用于活性剂的空间和时间可编程递送的系统。 当口服给药时，可以将系统长时间保留在胃区域。 它包括一个芯，一个或多个涂层在芯上的层和预制的中空空间。 本发明还涉及用于制备该系统的方法和一种治疗/预防疾病的方法，通过向有需要的受试者施用本发明的系统。

    NOVEL ORAL DELIVERY OF DESMOPRESSIN AND ITS SALTS
    10.
    发明申请
    NOVEL ORAL DELIVERY OF DESMOPRESSIN AND ITS SALTS 审中-公开
    DESMOPRESSIN及其销售的口头交付

    公开(公告)号：WO2007083323A2

    公开(公告)日：2007-07-26

    申请号：PCT/IN2007/000022

    申请日：2007-01-19

    Applicant: PANACEA BIOTEC LIMITED. ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

    IPC: A61K38/08 ,  A61K9/22

    CPC classification number: A61K9/4808 ,  A61K9/1617 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/5084 ,  A61K38/11

    Abstract: The invention describes a modified release oral dosage form of desmopressin which upon administration releases two or more amounts of desmopressin. The dosage form comprises of individual dosage units, such as an immediate release dosage unit and one or more delayed release dosage units, each comprising of a suitable amount of desmopressin, released after a predetermined time interval. The dosage form of the invention provides a release profile, adapted such that the dosage form exhibits improved efficacy for a prolonged duration of action and provides for an overall superior management of antidiuretic therapy. The invention also provides for method of manufacture of the dosage form of the invention and also method of treatment of diseases such as diabetes insipidus, nocturnal enuresis, nocturia and urinary incontinence in a mammal in need of such treatment.

    Abstract translation: 本发明描述了去氨加压素的改良释放口服剂型，其在施用时释放出两种或更多量的去氨加压素。 剂型包括单个剂量单位，例如立即释放剂量单位和一个或多个缓释剂量单位，每个剂量单位包含在预定时间间隔后释放的合适量的去氨加压素。 本发明的剂型提供释放曲线，适于使得剂型在延长的作用时间内表现出改进的功效，并且提供抗利尿治疗的总体优越的管理。 本发明还提供了在需要这种治疗的哺乳动物中制备本发明的剂型的方法以及治疗诸如尿崩症，夜间遗尿，夜尿和尿失禁的疾病的方法。

Patent Agency Ranking